Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $120,137.64 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $120,137.64. Following the completion of the sale, the insider now directly owns 84,489 shares in the company, valued at $2,571,000.27. This represents a 4.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Nur Nicholson also recently made the following trade(s):

• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $30.00 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $71.90. The business has a fifty day moving average of $32.08 and a 200-day moving average of $33.15. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of -14.78 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period in the previous year, the firm posted ($1.17) EPS. The company’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. raised its holdings in Apellis Pharmaceuticals by 42.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after acquiring an additional 39,931 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares during the period. Algert Global LLC increased its stake in Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in Apellis Pharmaceuticals during the third quarter worth about $1,370,000. Finally, GSA Capital Partners LLP purchased a new position in Apellis Pharmaceuticals during the third quarter worth about $824,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on APLS shares. Piper Sandler cut their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company cut their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Mizuho decreased their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Finally, Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target for the company. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).